

**COMPOSITIONS COMPRISING DOPAMINE REUPTAKE
INHIBITORS AND METHODS OF MAKING AND USING THE SAME**

ABSTRACT

5 Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.